ライフサイエンスコーパス: transplantation outcome

1 te engraftment of GE-HSPCs and improve their transplantation outcome.

2 P = 0.0012) had the highest correlation with transplantation outcome.

3 ctively shortened dHT without affecting lung transplantation outcome.

4 tomy time (dPT), and influenced LiT and lung transplantation outcome.

5 tter methods are still needed for predicting transplantation outcome.

6 antibody-mediated-rejection, and unfavorable transplantation outcome.

7 on of SCID babies from infection and improve transplantation outcome.

8 orrelated and were significant predictors of transplantation outcome.

9 can potentially have a significant impact on transplantation outcome.

10 tential impact for immune responsiveness and transplantation outcome.

11 ogenic compounds could further improve islet transplantation outcome.

12 to see whether IFN pretreatment compromised transplantation outcome.

13 justment of the dialysis method can optimize transplantation outcome.

14 d the effect of a BMI >25 on long-term renal transplantation outcome.

15 re reduced or absent in patients with a poor transplantation outcome.

16 -associated pathologies without jeopardizing transplantation outcomes.

17 orate liver IRI and improve orthotopic liver transplantation outcomes.

18 are known to be associated with adverse post-transplantation outcomes.

19 s a serious clinical problem affecting liver transplantation outcomes.

20 e access to transplantation and improve post-transplantation outcomes.

21 at the organ and cell levels, with impact on transplantation outcomes.

22 into autoimmune risk prediction and improved transplantation outcomes.

23 the ability of these metrics to predict post-transplantation outcomes.

24 ophage plasticity and polarization influence transplantation outcomes.

25 ixed regarding the impact of opioids on lung transplantation outcomes.

26 therapeutics are required to improve kidney transplantation outcomes.

27 sion differences may be involved in the post-transplantation outcomes.

28 idate genes or their regulatory regions with transplantation outcomes.

29 fore transplantation is associated with poor transplantation outcomes.

30 (AKI) is often limited by unpredictable post-transplantation outcomes.

31 immune activation is a determinant of kidney transplantation outcomes.

32 preparative regimens to improve therapeutic transplantation outcomes.

33 worse early mortality, hospitalization, and transplantation outcomes.

34 plication that significantly limits positive transplantation outcomes.

35 moral suppression to improve transfusion and transplantation outcomes.

36 copenia by deep learning would predict heart transplantation outcomes.

37 ssive medication regimens, thereby improving transplantation outcomes.

38 of the intestinal environment may influence transplantation outcomes.

39 length with MDS disease characteristics and transplantation outcomes.

40 orative research initiatives in the field of transplantation outcomes.

41 uld monitor islet mass might help to improve transplantation outcomes.

42 ed transplantation to achieve desirable post-transplantation outcomes.

43 nce the occurrence of autoimmune disease and transplantation outcomes.

44 identify a target group for improving kidney transplantation outcomes.

45 ht be crucial for improving long-term kidney transplantation outcomes.

46 ens new therapeutic options to improve liver transplantation outcomes.

47 HCT, we conducted an international survey of transplantation outcomes.

48 ntify individuals at risk for adverse kidney transplantation outcomes.

49 tic intervention and improvement of clinical transplantation outcomes.

50 y to develop risk-score categories for major transplantation outcomes.

51 egulation of immune responses that determine transplantation outcomes.

52 ies will be of assistance in improving islet transplantation outcomes.

53 and recipient age are factors that influence transplantation outcomes.

54 for improving HSPC mobilization and thereby transplantation outcomes.

55 may be a useful strategy in improving islet transplantation outcomes.

56 f 2 mg/kg per day) does not compromise major transplantation outcomes.

57 s unclear what impact G-CSF has on long-term transplantation outcomes.

58 success are defined for reporting on uterus transplantation outcomes: (1) technical, (2) menstruatio

59 Differences in kidney transplantation outcomes across GN subtypes have rarely

60 cal, and umbilical cord blood), and compared transplantation outcomes across three epochs (epoch 1: 2

61 Postkidney transplantation outcomes among patients with Fabry disea

62 s and the effect of age on waitlist and post-transplantation outcomes and on transplant-related survi

63 sociation of osmoregulation performance with transplantation outcomes and subsequent kidney function.

64 Corneal transplantation outcomes are generally less favorable in

65 This study sought to investigate post-transplantation outcomes as a function of race and panel

66 We review the pediatric stem cell transplantation outcomes as well as the pediatric experi

67 Using Cox regression analysis, we compared transplantation outcomes between groups.

68 We sought to compare kidney transplantation outcomes between Veterans Affairs (VA) a

69 vention RCTs hold potential to benefit organ transplantation outcomes but face unique research ethics

70 lung microbiome has been implicated in later transplantation outcomes but has not been investigated i

71 the loss of these BH3-only proteins improves transplantation outcome, but recipients might be exposed

72 umoral desensitization will not only improve transplantation outcomes, but also reveal an unexpected

73 Risk factors for transplantation outcomes by conditioning regimen groups

74 wearable artificial lung could improve lung transplantation outcomes by easing implementation of phy

75 flows and hold potential for improving heart transplantation outcomes by enhancing graft selection an

76 vances in biomaterials can improve pre-/post-transplantation outcomes by integrating biophysiochemica

77 linic as induction therapy aiming to improve transplantation outcomes by reducing the need for long-t

78 dial infarction or stroke, and improve organ transplantation outcomes by sustaining graft oxygenation

79 Moreover, transplantation outcome can be improved by administering

80 influence graft-versus-host disease or other transplantation outcomes can provide additional clinical

81 antation were higher in patients with a good transplantation outcome compared with those patients who

82 a genotyping array tailored specifically for transplantation outcomes containing 722 147 single nucle

83 We aimed to see if SPK transplantation outcomes differed between recipients fro

84 Donor KIR genotype influenced transplantation outcome for AML but not ALL.

85 hat iron overload plays an important role in transplantation outcome for patients with acute leukemia

86 Liver transplantation outcomes for HCC in these patients, howe

87 diting strategy has the potential to improve transplantation outcomes for regenerative therapies in t

88 S data show no net advantage in the ultimate transplantation outcome, graft survival.

89 s I or II antigens of a donor panel on heart transplantation outcome has not been extensively studied

90 The importance of HLA matching for renal transplantation outcomes has been appreciated for severa

91 ignificance of this drug-drug interaction on transplantation outcomes has not been determined.

92 The influence of DSA-SPA on repeat renal transplantation outcomes has not been previously studied

93 Kidney transplantation outcomes have advanced significantly wit

94 Genetic association studies of transplantation outcomes have been hampered by small sam

95 Genetic studies in kidney transplantation outcomes have started to assess the effe

96 additional islet-helper cells would improve transplantation outcome in diabetic mice.

97 nhibitory KIR can be a prognostic factor for transplantation outcome in HLA-identical sibling transpl

98 _INS mRNA and SI_16h insulin predicted islet transplantation outcome in nonobese diabetic (NOD) scid

99 To identify useful prognostic indicators of transplantation outcome in postimatinib therapeutic inte

100 cant contribution of donor-activating KIR to transplantation outcome in these patients.

101 an leukocyte antigen mismatch ("vector") and transplantation outcomes in 1202 recipients of single CB

102 We correlated gene expression profiles with transplantation outcomes in 327 diabetic mice, each rece

103 immunity-related GTPase family, M [IRGM]) on transplantation outcomes in 390 US patients and their ma

104 idence of EBV reactivation and its impact on transplantation outcomes in 71 patients undergoing haplo

105 H-2(d)) to assess alloimmunization and islet transplantation outcomes in Akita recipients.

106 and structural factors contributing to poor transplantation outcomes in kidney recipients of African

107 he next decade that are envisaged to improve transplantation outcomes in patients with advanced IPF.

108 The purpose of this study was to compare transplantation outcomes in patients with hematologic ma

109 f the lung allocation score on wait-list and transplantation outcomes in patients with idiopathic pul

110 ctor alpha blockade failed to improve kidney transplantation outcomes in the CTOT-19 trial that teste

111 ring several strategies to improve alloislet transplantation outcomes in the future.

112 The best transplantation outcomes in Wiskott-Aldrich syndrome are

113 evaluated the association of mutations with transplantation outcomes, including overall survival, re

114 Disparities in access to care and transplantation outcomes, including prolonged waitlist t

115 rate of infection and significantly improved transplantation outcome irrespective of donor choice, co

116 onor cells per kilogram recipient weight) on transplantation outcome is controversial and may differ

117 Because of the high cost, interest in transplantation outcomes is particularly intense.

118 ole of patient socioeconomic status (SES) in transplantation outcomes is poorly understood because of

119 h other and which have the greater impact on transplantation outcomes is, however, not clear.

120 The extent to which transplantation outcome may be improved with donor match

121 Factors associated with a good transplantation outcome need to be identified in order t

122 of Health-sponsored "APOL1 Long-term Kidney Transplantation Outcomes" Network will determine whether

123 MSC-based co-culture system to optimize the transplantation outcome of clustered regularly interspac

124 We report transplantation outcomes of 258 children with Hurler syn

125 pe and conditioning regimen intensity on the transplantation outcomes of in patients with sickle cell

126 We report donation and transplantation outcomes of our first 90 OPO-based NRP n

127 whether there were differences in postliver transplantation outcomes of patients with AHC when compa

128 Using similar models, waitlist and transplantation outcomes of patients with diabetes melli

129 cts of room-air oxygenation on pre- and post-transplantation outcomes of patients with HPS.

130 composite allograft (VCA) procurement on the transplantation outcomes of the concomitantly recovered

131 ratified Cox proportional hazards model, the transplantation outcomes of the SLE patients were compar

132 relating graft characteristics with clinical transplantation outcomes, on appropriate typing strategi

133 oes not appear to be associated with adverse transplantation outcomes over the first 3 years; however

134 xic therapy with double autologous stem cell transplantation, outcome remains poor for children with

135 strong gliotic response, and otherwise poor transplantation outcome (Rho(-/-)), leading to an eightf

136 l to identify patients at high risk for poor transplantation outcomes, supporting informed treatment

137 be used to supply needed islets for improved transplantation outcomes that cure diabetes.

138 ibrogenic phenotypes (M2 cells); they affect transplantation outcomes via diverse mechanisms.

139 t of both access to transplantation and post-transplantation outcomes, warranting a focused study of

140 Transplantation outcome was post-transplant glycemic con

141 he association of donor characteristics with transplantation outcomes was examined using either logis

142 To identify factors influencing transplantation outcome, we studied 452 recipients of HL

143 To identify predictive factors for transplantation outcome, we studied 519 patients with MD

144 of CHIP and the impact of clonal dynamics on transplantation outcomes, we created a mathematical mode

145 The effects of 9 individual variables on transplantation outcomes were also examined, and the sta

146 Transplantation outcomes were compared between 1,052 URD

147 Thus, transplantation outcomes were compared in the prospectiv

148 Transplantation outcomes were not affected by the prepar

149 We only included studies where liver transplantation outcomes were reported.

150 n Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolim

151 nosuppression offers the promise of improved transplantation outcomes with reduced drug toxicity.

152 al transplant patients with SLE had inferior transplantation outcomes, with more than twice the risk

153 r cells during engraftment but also improves transplantation outcome without signs of adverse patholo